Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Partners with GPCR to Develop Burixafor & Taigexyn\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Burixafor

    Menu

    Burixafor

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TaiGen Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Partners with GPCR to Develop Burixafor & Taigexyn®

              Details:

              Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.

              Lead Product(s): Burixafor

              Therapeutic Area: Immunology Product Name: TG-0054

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: GPCR Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY